<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
<head>
<meta http-equiv="Content-Type" content=
"text/html; charset=utf-8" /><!-- AppResources meta begin -->

<script type="text/javascript">
//<![CDATA[
var ncbi_startTime = new Date();
//]]>
</script><!-- AppResources meta end -->
<!-- TemplateResources meta begin -->
<meta name="paf_template" content="" />
<!-- TemplateResources meta end -->
<!-- Logger begin -->
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_pdid" content="article" />
<meta name="ncbi_acc" content="" />
<meta name="ncbi_domain" content="brjclinpharm" />
<meta name="ncbi_report" content="record" />
<meta name="ncbi_type" content="fulltext" />
<meta name="ncbi_objectid" content="" />
<meta name="ncbi_pcid" content="/articles/PMC2015056/" />
<meta name="ncbi_app" content="pmc" /><!-- Logger end -->
<title>The effects of ketoconazole on ziprasidone pharmacokinetics
—a placebo-controlled crossover study in healthy volunteers</title>
<!-- AppResources external_resources begin -->
<link rel="stylesheet" href="/core/jig/1.14.4/css/jig.min.css" />
<script type="text/javascript" src=
"/core/jig/1.14.4/js/jig.min.js">
</script><!-- AppResources external_resources end -->
<!-- Page meta begin -->
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" />
<link rel="canonical" href="/pmc/articles/PMC2015056/" />
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" />
<meta name="citation_journal_title" content=
"British Journal of Clinical Pharmacology" />
<meta name="citation_title" content=
"The effects of ketoconazole on ziprasidone pharmacokinetics —a placebo-controlled crossover study in healthy volunteers" />
<meta name="citation_authors" content=
"J J Miceli, M Smith, L Robarge, T Morse, A Laurent" />
<meta name="citation_date" content="January 2000" />
<meta name="citation_issue" content="Suppl 1" />
<meta name="citation_volume" content="49" />
<meta name="citation_firstpage" content="71S" />
<meta name="citation_doi" content=
"10.1046/j.1365-2125.2000.00156.x" />
<meta name="citation_abstract_html_url" content=
"/pmc/articles/PMC2015056/?report=abstract" />
<meta name="citation_pmid" content="10771458" />
<meta name="DC.Title" content=
"The effects of ketoconazole on ziprasidone pharmacokinetics —a placebo-controlled crossover study in healthy volunteers" />
<meta name="DC.Type" content="Text" />
<meta name="DC.Publisher" content="Wiley-Blackwell" />
<meta name="DC.Contributor" content="J J Miceli" />
<meta name="DC.Contributor" content="M Smith" />
<meta name="DC.Contributor" content="L Robarge" />
<meta name="DC.Contributor" content="T Morse" />
<meta name="DC.Contributor" content="A Laurent" />
<meta name="DC.Date" content="2000 Jan" />
<meta name="DC.Identifier" content=
"10.1046/j.1365-2125.2000.00156.x" />
<meta name="DC.Language" content="en" />
<meta property="og:title" content=
"The effects of ketoconazole on ziprasidone pharmacokinetics —a placebo-controlled crossover study in healthy volunteers" />
<meta property="og:type" content="article" />
<meta property="og:description" content=
"To assess the effects of multiple oral doses of ketoconazole on the single-dose pharmacokinetics of oral ziprasidone HCl.This was a 14-day, open-label, randomized, crossover study in 14 healthy subjects aged 18–31 years. Group 1 received oral ..." />
<meta property="og:url" content=
"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2015056/" />
<meta property="og:site_name" content="PubMed Central (PMC)" />
<meta property="og:image" content=
"http://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png" />
<meta name="twitter:card" content="summary" />
<meta name="twitter:site" content="@ncbi" />
<link rel="stylesheet" href="/corehtml/pmc/css/3.4/pmc.min.css"
type="text/css" />
<link rel="stylesheet" href=
"/corehtml/pmc/css/3.4/pmc_extras_prnt.min.css" type="text/css"
media="print" />
<script type="text/javascript" src=
"/corehtml/pmc/js/common.min.js">
//<![CDATA[
//
//]]>
</script>
<script type="text/javascript" src=
"/corehtml/pmc/js/NcbiTagServer.min.js">
//<![CDATA[
//
//]]>
</script>
<meta name="citationexporter" content=
"backend:'/pmc/utils/ctxp/'" />
<script type="text/javascript" src=
"/corehtml/pmc/ctxp/jquery.citationexporter.js">
//<![CDATA[
//
//]]>
</script>
<link rel="stylesheet" href=
"/corehtml/pmc/ctxp/citationexporter.css" type="text/css" />
<script type="text/javascript" src=
"/core/mathjax/2.6.1/MathJax.js?config=/corehtml/pmc/js/mathjax-config-classic.3.4.js">
</script>
<script type="text/javascript" src=
"/corehtml/pmc/js/large-obj-scrollbars.min.js">
</script>
<script type="text/javascript">
//<![CDATA[
window.name="mainwindow";
//]]>
</script>
<style type="text/css">
/*<![CDATA[*/
.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-brjclinpharm.gif);background-size: auto, contain}
/*]]>*/
</style>

<style type="text/css">
/*<![CDATA[*/
.print-view{display:block}
/*]]>*/
</style>

<style type="text/css">
/*<![CDATA[*/
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
/*]]>*/
</style>
<link rel="alternate" type="application/epub+zip" href=
"/pmc/articles/PMC2015056/epub/" />
<link rel="alternate" type="application/pdf" href=
"/pmc/articles/PMC2015056/pdf/bcp0049-071S.pdf" />
<!-- Page meta end -->
<link rel="shortcut icon" href=
"//www.ncbi.nlm.nih.gov/favicon.ico" />
<meta name="ncbi_phid" content=
"F4FC5E3F6FE7D72100000000000CE69D" />
<link type="text/css" rel="stylesheet" href=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/css/3852956/3985586/3808861/3734262/3974050/3917732/251717/4048120/3846471/14534/45193/3988413/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4052581/9685/3549676/3609192/3609193/3609213/3395586/3855312.css" />
<link type="text/css" rel="stylesheet" href=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/css/3411343/3882866/3929378.css"
media="print" />
</head>
<body class="article">
<div class="grid">
<div class="col twelve_col nomargin shadow">
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
<div class="sysmessages"><noscript>
<p class="nojs"><strong>Warning:</strong> The NCBI web site
requires JavaScript to function. <a href=
"/guide/browsers/#enablejs" title="Learn how to enable JavaScript"
target="_blank">more...</a></p>
</noscript></div>
<!--/.sysmessage-->
<div class="wrap">
<div class="page">
<div class="top">
<div class="universal_header" id="universal_header">
<ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id=
"navcontent">
<li class=
"ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt">
<a class="ui-ncbimenu-link-first" href="/" role="banner" title=
"NCBI Home" id="ncbihome" accesskey="1"><span class=
"offscreen_noflow">NCBI</span><img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/28977"
class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"#maincontent" title="Skip to the content" tabindex="0" accesskey=
"3">Skip to main content</a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"#navcontent" title="Skip to the navigation" tabindex="0"
accesskey="4">Skip to navigation</a></li>
<li id="resource-menu" class=
"topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset">
<a class=
"ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown"
href=
"/static/header_footer_ajax/submenu/#resources">Resources</a></li>
<li id="all-howtos-menu" class=
"topmenu ui-helper-reset ui-ncbimenu-item-first"><a class=
"ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown"
href="/static/header_footer_ajax/submenu/#howto">How To</a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"/guide/browsers/#accesskeys" title="About My NCBI Accesskeys"
tabindex="0" accesskey="0">About NCBI Accesskeys</a></li>
</ul>
<div class="myncbi"><span id="myncbiusername" style=
"display:none"><a href="/account/settings/" id="mnu" title=
"Edit account settings"></a></span><a accesskey="2" href="/myncbi/"
id="myncbi" style="display:none">My NCBI</a><a href="/account/" id=
"sign_in">Sign in to NCBI</a><a href="/account/signout/" id=
"sign_out" style="display:none">Sign Out</a></div>
</div>
<div class="header">
<div class="res_logo">
<h1 class="img_logo"><a href="/pmc/" class=
"pmc_logo offscreen">PMC</a></h1>
<div class="NLMLogo"><a href="http://www.nlm.nih.gov/" title=
"US National Library of Medicine">US National Library of
Medicine</a><br />
<a href="http://www.nih.gov/" title=
"National Institutes of Health">National Institutes of
Health</a></div>
</div>
<div class="search">
<form method="get" action="/pmc/">
<div class="search_form"><label for="database" class=
"offscreen_noflow">Search database</label><select id="database">
<optgroup label="Recent">
<option value="pmc" selected="selected" class="last" data-ac_dict=
"pmc-search-autocomplete">PMC</option>
</optgroup>
<optgroup label="All">
<option value="gquery">All Databases</option>
<option value="assembly">Assembly</option>
<option value="bioproject">BioProject</option>
<option value="biosample">BioSample</option>
<option value="biosystems">BioSystems</option>
<option value="books">Books</option>
<option value="clinvar">ClinVar</option>
<option value="clone">Clone</option>
<option value="cdd">Conserved Domains</option>
<option value="gap">dbGaP</option>
<option value="dbvar">dbVar</option>
<option value="epigenomics">Epigenomics</option>
<option value="nucest">EST</option>
<option value="gene">Gene</option>
<option value="genome">Genome</option>
<option value="gds">GEO DataSets</option>
<option value="geoprofiles">GEO Profiles</option>
<option value="nucgss">GSS</option>
<option value="gtr">GTR</option>
<option value="homologene">HomoloGene</option>
<option value="medgen">MedGen</option>
<option value="mesh">MeSH</option>
<option value="ncbisearch">NCBI Web Site</option>
<option value="nlmcatalog">NLM Catalog</option>
<option value="nuccore">Nucleotide</option>
<option value="omim">OMIM</option>
<option value="pmc" data-ac_dict="pmc-search-autocomplete">
PMC</option>
<option value="popset">PopSet</option>
<option value="probe">Probe</option>
<option value="protein">Protein</option>
<option value="proteinclusters">Protein Clusters</option>
<option value="pcassay">PubChem BioAssay</option>
<option value="pccompound">PubChem Compound</option>
<option value="pcsubstance">PubChem Substance</option>
<option value="pubmed">PubMed</option>
<option value="pubmedhealth">PubMed Health</option>
<option value="snp">SNP</option>
<option value="sra">SRA</option>
<option value="structure">Structure</option>
<option value="taxonomy">Taxonomy</option>
<option value="toolkit">ToolKit</option>
<option value="toolkitall">ToolKitAll</option>
<option value="toolkitbook">ToolKitBook</option>
<option value="toolkitbookgh">ToolKitBookgh</option>
<option value="unigene">UniGene</option>
</optgroup>
</select>
<div class="nowrap"><label for="term" class="offscreen_noflow"
accesskey="/">Search term</label>
<div class="nowrap"><input type="text" name="term" id="term" title=
"Search PMC. Use up and down arrows to choose an item from the autocomplete."
value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" config=
"dictionary:'pmc-search-autocomplete',disableUrl:'NcbiSearchBarAutoComplCtrl'"
autocomplete="off" data-sbconfig=
"ds:'no',pjs:'no',afs:'yes'" /></div>
<button id="search" type="submit" class="button_search nowrap" cmd=
"go">Search</button></div>
</div>
</form>
<ul class="searchlinks inline_list">
<li><a href="/pmc/limits/">Limits</a></li>
<li><a href="/pmc/advanced/">Advanced</a></li>
<li><a href="/pmc/journals/">Journal list</a></li>
<li class="help"><a target="_blank" href=
"/books/NBK3825/">Help</a></li>
</ul>
</div>
</div>
<!--<component id="Page" label="headcontent"/>--></div>
<div class="content"><!-- site messages -->
<div class="container">
<div id="maincontent" class="content eight_col col">
<div class="navlink-box">
<ul class="page-breadcrumbs inline_list small">
<li class="journal-list"><a href="/pmc/journals/" class=
"navlink">Journal List</a></li>
<li class="archive-page"><a class="navlink" href=
"/pmc/journals/279/">Br J Clin Pharmacol</a></li>
<li class="issue-page"><a class="navlink" href=
"/pmc/issues/151586/">v.49(Suppl 1); 2000 Jan</a></li>
<li class="accid">PMC2015056</li>
</ul>
</div>
<!-- Journal banner -->
<div class="pmc-page-banner whole_rhythm">
<div><img src="/corehtml/pmc/pmcgifs/logo-brjclinpharm.gif" alt=
"Logo of brjclinpharm" usemap="#logo-imagemap" /><map id=
"logo-imagemap" name="logo-imagemap">
<area alt="Link to Publisher's site" title=
"Link to Publisher's site" shape="default" coords="0,0,499,74"
href="http://www.blackwellpublishing.com/journal.asp?ref=0306-5251"
target="pmc_ext" ref=
"reftype=publisher&amp;article-id=2015056&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" />
</map></div>
</div>
<!--component id='MainPortlet' label='search-reference'/-->
<!-- Book content -->
<div class="">
<div class=
"hide-overflow article lit-style content pmc-wm slang-all page-box">
<!--main-content-->
<div class="jig-ncbiinpagenav" data-jigconfig=
"smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden'">
<div class="fm-sec half_rhythm no_top_margin">
<div class="fm-citation half_rhythm no_top_margin clearfix">
<div class="small">
<div class="inline_block eight_col va_top">
<div>
<div><span class="cit">Br J Clin Pharmacol. 2000 Jan; 49(Suppl 1):
71S–76S.</span></div>
<div><span class="doi">doi:&nbsp; <a href=
"http://dx.doi.org/10.1046%2Fj.1365-2125.2000.00156.x" target=
"pmc_ext" ref=
"reftype=other&amp;article-id=2015056&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">
10.1046/j.1365-2125.2000.00156.x</a></span></div>
</div>
</div>
<div class=
"inline_block four_col va_top show-overflow align_right">
<div class="fm-citation-ids">
<div class="fm-citation-pmcid"><span class=
"fm-citation-ids-label">PMCID:</span> <span>PMC2015056</span></div>
</div>
</div>
</div>
</div>
<h1 class="content-title">The effects of ketoconazole on
ziprasidone pharmacokinetics —a placebo-controlled crossover study
in healthy volunteers</h1>
<div class="half_rhythm">
<div class="contrib-group fm-author"><a href=
"/pubmed/?term=Miceli%20JJ%5Bauth%5D">J J Miceli</a>,<sup>1</sup>
<a href="/pubmed/?term=Smith%20M%5Bauth%5D">M
Smith</a>,<sup>2</sup> <a href=
"/pubmed/?term=Robarge%20L%5Bauth%5D">L Robarge</a>,<sup>1</sup>
<a href="/pubmed/?term=Morse%20T%5Bauth%5D">T
Morse</a>,<sup>1</sup> and <a href=
"/pubmed/?term=Laurent%20A%5Bauth%5D">A
Laurent</a><sup>3</sup></div>
</div>
<div class="fm-panel small half_rhythm">
<div class="fm-authors-info fm-panel hide half_rhythm" id=
"id1430761_ai" style="display:none">
<div class="fm-affl" lang="en"><sup>1</sup>Department of Clinical
Research, Pfizer Central Research, Groton, CT 06340, USA</div>
<div class="fm-affl" lang="en"><sup>2</sup>Pfizer Central Research,
Ramsgate Road, Sandwich, Kent, CT13 9NT, UK</div>
<div class="fm-affl" lang="en"><sup>3</sup>706 A Ben White
Boulevard West, Austin, TX 78704–7016, USA</div>
<div id="cor1"><em>Correspondence:</em> Dr J. J. Miceli, Pfizer
Central Research, Eastern Point Road, Groton, Connecticut 06340,
USA.</div>
</div>
<div class="togglers"><a href="#" class="pmctoggle" rid=
"id1430761_ai">Author information <span>►</span></a> <a href="#"
class="pmctoggle" rid="id1430761_cpl">Copyright and License
information <span>►</span></a></div>
<div class="fm-article-notes fm-panel half_rhythm"></div>
<div class="fm-cpl-info fm-panel hide half_rhythm" id=
"id1430761_cpl" style="display:none">
<div class="fm-copyright half_rhythm"><a href=
"/pmc/about/copyright.html">Copyright</a> © 2000 Blackwell Science
Ltd</div>
</div>
</div>
<div class="links-box fm-panel whole_rhythm">
<div class="small">
<div>This article has been <a href=
"/pmc/articles/PMC2015056/citedby/">cited by</a> other articles in
PMC.</div>
</div>
</div>
</div>
<div class="sec"></div>
<div id="__abstractid1144453" lang="en" class="tsec sec">
<h2 class="head no_bottom_margin" id="__abstractid1144453title">
Abstract</h2>
<!--article-meta-->
<div>
<div id="__sec1" class="sec sec-first">
<h3>Aims</h3>
<p id="__p1" class="p p-first-last">To assess the effects of
multiple oral doses of ketoconazole on the single-dose
pharmacokinetics of oral ziprasidone HCl.</p>
</div>
<div id="__sec2" class="sec">
<h3>Methods</h3>
<p id="__p2" class="p p-first-last">This was a 14-day, open-label,
randomized, crossover study in 14 healthy subjects aged 18–31
years. Group 1 received oral ketoconazole 400 mg once daily for 6
days, followed by a 2 day wash-out period and 6 days of placebo
administration. Group 2 received placebo followed by ketoconazole.
Single oral doses of ziprasidone HCl 40 mg were administered on
days 5 and 13 in both groups. Ziprasidone pharmacokinetic
parameters were compared between placebo and ketoconazole
administration periods.</p>
</div>
<div id="__sec3" class="sec">
<h3>Results</h3>
<p id="__p3" class="p p-first-last">Co-administration of
ziprasidone with ketoconazole was associated with a modest increase
in ziprasidone exposure; mean ziprasidone AUC(0,∞) increased by
33%, from 899 ng ml<sup>−1</sup> h with placebo to 1199
ngml<sup>−1</sup> h with ketoconazole. Mean
<em>C</em><sub>max</sub> increased by 34%, from 89 ng
ml<sup>−1</sup> to 119 ng ml<sup>−1</sup>, respectively. The
treatment effect on both of these parameters was statistically
significant (<em>P</em>&lt; 0.02). Most adverse events were of mild
intensity. There were no serious adverse events, laboratory
abnormalities, abnormal ECGs, or clinically significant alterations
in vital signs throughout the study.</p>
</div>
<div id="__sec4" class="sec sec-last">
<h3>Conclusions</h3>
<p id="__p4" class="p p-first-last">The concurrent administration
of ketoconazole and ziprasidone led to modest, statistically
significant increases in ziprasidone exposure, although the changes
seen were not considered clinically relevant. This suggests that
other inhibitors of CYP3A4 are unlikely to significantly affect the
pharmacokinetics of ziprasidone.</p>
</div>
</div>
<div class="sec"><strong class="kwd-title">Keywords:</strong>
<span class="kwd-text">interaction, ketoconazole, pharmacokinetics,
ziprasidone</span></div>
</div>
<div id="__sec5" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec5title">
Introduction</h2>
<p id="__p5" class="p p-first">Studies conducted <em>in vitro</em>
have shown that the oxidative metabolism of ziprasidone is mediated
primarily by isoform 3A4 of the hepatic cytochrome P450 system
(CYP3A4) [<a href="#b1" rid="b1" class=" bibr popnode">1</a>,
<a href="#b2" rid="b2" class=" bibr popnode">2</a>], and that
ziprasidone does not inhibit cytochromes CYP1A2, CYP2C9, CYP2C19,
CYP2D6, or CYP3A4 at clinically relevant concentrations [<a href=
"#b2" rid="b2" class=" bibr popnode">2</a>, <a href="#b3" rid="b3"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012739">3</a>]. Ziprasidone is therefore unlikely to
interfere with the cytochrome-dependent metabolism and the
pharmaco-kinetics of a large number of widely used drugs such as
antiarrhythmics, antihistamines, tricyclic antidepressants,
β-adrenoceptor blockers, and calcium channel antagonists.</p>
<p id="__p6">Phase I studies in healthy subjects have also
demonstrated no clinically significant pharmacokinetic interactions
between ziprasidone and cimetidine (which inhibits several isoforms
of CYP including CYP3A4), ethinyloestradiol (which is metabolized
by CYP3A4), or carbamazepine (a substrate for, and potent inducer
of, CYP3A4), suggesting that co-administration with other CYP3A4
inhibitors or inducers will not present a problem [<a href="#b4"
rid="b4" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012730">4</a>–<a href="#b6" rid="b6" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012735">6</a>].</p>
<p id="__p7">Ketoconazole, an imidazole derivative and
broad-spectrum antifungal treatment for superficial and systemic
fungal infections, is a potent inhibitor of CYP3A4. It has been
shown to reduce the oxidative metabolism of drugs such as warfarin
and some benzodiazapines [<a href="#b7" rid="b7" class=
" bibr popnode">7</a>], as well as antihistamines and antacids that
share the CYP3A4 pathway [<a href="#b8" rid="b8" class=
" bibr popnode tag_hotlink tag_tooltip" id="__tag_311012737">8</a>,
<a href="#b9" rid="b9" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012741">9</a>].</p>
<p id="__p8" class="p p-last">The following open-label, randomized,
placebo-controlled, crossover study in healthy volunteers evaluated
the effect of ketoconazole inhibition of CYP3A4 on ziprasidone
pharmacokinetics.</p>
</div>
<div id="__sec6" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec6title">Methods</h2>
<div id="__sec7" class="sec sec-first">
<h3>Subjects</h3>
<p id="__p9" class="p p-first">Fourteen healthy individuals (men or
women) 18–45 years old, weighing no more than 91 kg and within 10%
of their ideal body weight for age, height, gender, and frame
[<a href="#b10" rid="b10" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012734">10</a>] were enrolled into the study. Subjects
with evidence or a history of clinically significant allergic
(except for untreated asymptomatic seasonal allergies),
haematological, renal, endocrine, pulmonary, gastrointestinal,
cardiovascular, hepatic, psychiatric, or neurological disease
(including all forms of epilepsy) were excluded. Smokers, subjects
with any condition that could affect drug absorption, and subjects
with known drug or alcohol dependence or drug allergies were also
excluded. Women were required to have been surgically sterilized,
or at least 2 years postmenopausal, or to have been using reliable
contraception for at least 3 months.</p>
<p id="__p10">Subjects were excluded if they had taken any
pre-scription medication (except contraceptives), over-the-counter,
or recreational drugs within 2 weeks, or any investigational drug
within 4 weeks of study entry. Alcohol and concomitant medications
were not allowed during the study.</p>
<p id="__p11" class="p p-last">The study had institutional review
board approval. All subjects gave informed written consent.</p>
</div>
<div id="__sec8" class="sec">
<h3>Protocol</h3>
<p id="__p12" class="p p-first">This was a randomized, open-label,
placebo-controlled, crossover study. Following screening, subjects
were randomized to two groups. Subjects in group 1 received
once-daily oral ketoconazole 200 mg after food on the morning of
day 1, which was increased to 400 mg on days 2–6. After a 2 day
wash-out period on days 7 and 8, they then received placebo on days
9–14. Subjects in group 2 were treated exactly as in group 1 except
that they received placebo on days 1–6 and ketoconazole on days
9–14. Single oral doses of ziprasidone HCl 40 mg were administered
on days 5 and 13. During the 14-day study period, subjects received
ketoconazole or placebo on an outpatient basis. However, subjects
were housed in the research facility under continuous medical
supervision for at least 12 h prior to, and 36 h after dosing with
ziprasidone on days 5 and 13.</p>
<p id="__p13" class="p p-last">Ziprasidone was administered with
100 ml water immediately after consumption of a standard high-fat
breakfast. Ketoconazole and placebo were taken with 50 ml water
after a light breakfast, except on day 5 (group 1) or day 13 (group
2) when they were co-administered with ziprasidone. When
ziprasidone was administered, subjects did not eat, lie down
(except for vital sign measurements), or drink caffeinated or
decaffeinated beverages for up to 4 h after dosing.</p>
</div>
<div id="__sec9" class="sec">
<h3>Pharmacokinetic sampling and analysis</h3>
<p id="__p14" class="p p-first">Blood samples were collected before
morning dosing on days 1, 4, 5, 6, 12, 13, and 14, in tubes
containing EDTA, for the determination of trough plasma
concentrations of ketoconazole. Plasma was separated from whole
blood samples by centrifugation within 1 h of collection. On days 5
and 13 (ziprasidone dosing days), blood samples were collected in
plain tubes (no preservative, anticoagulant, or serum separator)
just before ziprasidone dosing and then 1, 2, 4, 6, 8, 12, 18, 24,
and 36 h after the morning ziprasidone dose. These samples were
allowed to clot at room temperature to extract serum for the
measurement of ziprasidone concentration. All samples were stored
at −20 °C until analysed for either ziprasidone or ketoconazole
concentrations.</p>
<p id="__p15" class="p p-last">Serum ziprasidone concentrations
were determined using h.p.l.c.) assay using a solid phase
extraction procedure and ultraviolet (u.v.) detection [<a href=
"#b11" rid="b11" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012732">11</a>]. This assay had a dynamic range of 1–250
ng ml<sup>−1</sup> with concentrations below 1 ng ml<sup>−1</sup>
reported as 0 ng ml<sup>−1</sup>. Trough plasma ketoconazole
concentrations were also assayed using a validated h.p.l.c. method
with u.v. detection. This assay had a dynamic range of 50–5000 ng
ml<sup>−1</sup>.</p>
</div>
<div id="__sec10" class="sec">
<h3>Data analysis</h3>
<p id="__p16" class="p p-first">The effect of ketoconazole on
ziprasidone pharmacokinetics was assessed by comparing
pharmacokinetic parameters on days 5 and 13 between both treatment
groups. Maximum observed serum concentrations of ziprasidone
(<em>C</em><sub>max</sub>), and the time at which
<em>C</em><sub>max</sub> occurred (<em>t</em><sub>max</sub>) were
determined directly from the experimental data. The terminal
elimination phase rate constant (λ<sub>z</sub>) was estimated from
individual concentration–time curves using least-squares regression
analysis of data obtained during the log-linear phase. The terminal
phase half-life of ziprasidone (<em>t</em><sub>½,z</sub>) was
calculated as ln 2/λ<sub>z</sub> and the mean half-life of
ziprasidone was estimated as ln 2/mean λ<sub>z</sub>.</p>
<p id="__p17">Total area under the concentration–time curve,
AUC(0,∞), was determined as the sum of AUC(0, <em>t</em>) and
AUC(<em>t</em>,∞). AUC(0, <em>t</em>) was estimated using linear
trapezoidal approximation, where <em>t</em> is the time of the last
sample with quantifiable concentrations of ziprasidone;
AUC(<em>t</em>, ∞) was estimated as <em>Cp</em><sub>est</sub>
/λ<sub>z</sub>, where <em>Cp</em><sub>est</sub> was the estimated
concentration at time <em>t</em>, based on regression analysis from
the log-concentration–time curve.</p>
<p id="__p18" class="p p-last">An estimated 14 subjects (seven to
receive ketoconazole and seven to receive placebo) were required to
detect a 50% difference in the change in AUC(0,∞) between the two
groups with 80% power and a 5% significance level. An analysis of
variance (<span class="small-caps">anova</span>) model containing
sequence, period, and treatment effects was used to analyse natural
log-transformed AUC(0,∞) and <em>C</em><sub>max</sub> in PROC GLM
of SAS® at the 5% significance level. Differences between
ziprasidone pharmacokinetic parameters with concomitant placebo and
ketoconazole treatments were estimated by comparing adjusted means
for groups 1 and 2, their variances, covariances and 95% confidence
limits, calculated using the SAS® LSMEANS function.</p>
</div>
<div id="__sec11" class="sec sec-last">
<h3>Tolerability assessments</h3>
<p id="__p19" class="p p-first">Tolerability assessments during the
study were clinical laboratory tests including liver function tests
(alkaline phosphatase, aspartate aminotransferase [SGOT], alanine
aminotransferase [SGPT], and total bilirubin) 24 h before day 1 and
on days 5 and 13, and vital sign measurements (blood pressure and
pulse rate) on days 1–6 and 9–14. Physical examinations were
performed at screening, on completion, or discontinuation from the
study.</p>
<p id="__p20" class="p p-last">Adverse events occurring during
study treatment and up to 6 days after the last day of dosing were
recorded using standard COSTART definitions and classified
according to the investigator’s assessment of intensity (mild,
moderate, severe) and causal relationship to study drug.</p>
</div>
</div>
<div id="__sec12" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec12title">Results</h2>
<div id="__sec13" class="sec sec-first">
<h3>Subjects</h3>
<p id="__p21" class="p p-first-last">A total of 14 subjects (6 men
and 8 women) were enrolled in the study. Mean age and body weights
of the men were 25.5 years (range 18–31 years) and 73.8 kg (range
68–83 kg), respectively. All six men were White. Mean age and
weight of the women were 29.3 years (range 22–44 years) and 58.8 kg
(range 49–68 kg), respectively. Six of the women were White, one
was Black and one was Hispanic. Thirteen subjects completed the
study. One subject discontinued from the study for personal
reasons, after taking placebo for 4 days in the second treatment
phase.</p>
</div>
<div id="__sec14" class="sec">
<h3>Pharmacokinetics</h3>
<p id="__p22" class="p p-first"><a href=
"/pmc/articles/PMC2015056/figure/fig01/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="fig01" rid-ob=
"ob-fig01" co-legend-rid="lgnd_fig01"><span>Figure 1</span></a>
shows the mean serum ziprasidone concentration–time curves on days
5 and 13 for both groups. Mean ziprasidone pharmacokinetic
parameters for both groups on days 5 and 13 are summarized in
<a href="/pmc/articles/PMC2015056/table/tbl1/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl1" rid-ob=
"ob-tbl1" co-legend-rid=""><span>Table 1</span></a>. Mean
pharmacokinetic parameters were similar in both groups following
administration of ziprasidone with ketoconazole. Following
administration of ziprasidone with placebo,
<em>t</em><sub>max</sub> occurred 3 h later in group 2 compared
with group 1; all other parameters were similar in both groups.
<span class="small-caps">anova</span> showed that there were no
significant effects on AUC(0,∞) and <em>C</em><sub>max</sub> of
either the sequence or the period in which the study drugs were
given (<a href="/pmc/articles/PMC2015056/table/tbl1/" target="true"
class="fig-table-link table figpopup" rid-figpopup="tbl1" rid-ob=
"ob-tbl1" co-legend-rid=""><span>Table 1</span></a>). Thus, data
from corresponding treatment phases of the two groups were combined
for analysis of treatment effects.</p>
<!--table ft1--><!--table-wrap mode=article t1-->
<div class="table-wrap iconblock ten_col whole_rhythm clearfix" id=
"tbl1"><a href="/pmc/articles/PMC2015056/table/tbl1/" target=
"table" rid-ob="ob-tbl1" rid-figpopup="tbl1" class=
"table img_link icnblk_img figpopup"><img alt="Table 1" title=
"Table 1" class="small-thumb" src=
"/pmc/articles/PMC2015056/table/tbl1/?report=thumb" src-large=
"/pmc/articles/PMC2015056/table/tbl1/?report=previmg" /></a>
<div class="icnblk_cntnt">
<div><a class="figpopup" href=
"/pmc/articles/PMC2015056/table/tbl1/" target="table" rid-figpopup=
"tbl1" rid-ob="ob-tbl1">Table 1</a></div>
<!--caption a4-->
<div><span>Mean±s.d. pharmacokinetic parameters for ziprasidone on
days 5 and 13 during placebo and ketoconazole
administration.</span></div>
</div>
</div>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="fig01"
co-legend-rid="lgnd_fig01"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC2015056/figure/fig01/" target="figure"
rid-figpopup="fig01" rid-ob="ob-fig01"><img src=
"/pmc/articles/PMC2015056/bin/bcp0049-071S-f1.gif" class=
"small-thumb" alt="Figure 1" title="Figure 1" src-large=
"/pmc/articles/PMC2015056/bin/bcp0049-071S-f1.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_fig01">
<div><a class="figpopup" href=
"/pmc/articles/PMC2015056/figure/fig01/" target="figure"
rid-figpopup="fig01" rid-ob="ob-fig01">Figure 1</a></div>
<!--caption a4-->
<div><span>Mean serum ziprasidone concentrations on days 5 and 13
for groups 1 and 2. Group 1, day 5 ketoconazole (♦), group 1 day 13
placebo (◊); group 2, day 5 placebo (▴), and group 2 day 13
ketoconazole (▵).</span></div>
</div>
</div>
<p id="__p29">Co-administration of ziprasidone with ketoconazole
was associated with an increase in overall ziprasidone exposure
compared with placebo (<a href=
"/pmc/articles/PMC2015056/table/tbl2/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl2" rid-ob=
"ob-tbl2" co-legend-rid=""><span>Table 2</span></a>). Adjusted mean
values for ziprasidone AUC(0,∞) increased by 33%, from 899 ng
ml<sup>−1</sup> h with placebo to 1199 ngml<sup>−1</sup> h with
ketoconazole. Corresponding adjusted mean <em>C</em><sub>max</sub>
values increased by 34%, from 89 ng ml<sup>−1</sup> with placebo to
119 ng ml<sup>−1</sup> with ketoconazole (<a href=
"/pmc/articles/PMC2015056/table/tbl2/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl2" rid-ob=
"ob-tbl2" co-legend-rid=""><span>Table 2</span></a>). These changes
were associated with a small increase in ziprasidone λ<sub>z</sub>
from 0.164 h<sup>−1</sup> (placebo) to 0.183 h<sup>−1</sup>
(ketoconazole), corresponding to a modest decrease in ziprasidone
<em>t</em><sub>½,z</sub> from 4.2 h (placebo) to 3.8 h
(ketoconazole). Adjusted mean values for ziprasidone
<em>t</em><sub>max</sub> were similar with values of 8.5 h for
placebo and 9.2 h for ketoconazole.</p>
<!--table ft1--><!--table-wrap mode=article t1-->
<div class="table-wrap iconblock ten_col whole_rhythm clearfix" id=
"tbl2"><a href="/pmc/articles/PMC2015056/table/tbl2/" target=
"table" rid-ob="ob-tbl2" rid-figpopup="tbl2" class=
"table img_link icnblk_img figpopup"><img alt="Table 2" title=
"Table 2" class="small-thumb" src=
"/pmc/articles/PMC2015056/table/tbl2/?report=thumb" src-large=
"/pmc/articles/PMC2015056/table/tbl2/?report=previmg" /></a>
<div class="icnblk_cntnt">
<div><a class="figpopup" href=
"/pmc/articles/PMC2015056/table/tbl2/" target="table" rid-figpopup=
"tbl2" rid-ob="ob-tbl2">Table 2</a></div>
<!--caption a4-->
<div><span>Summary of adjusted (<span class=
"small-caps">anova</span>) mean pharmacokinetic parameters for
ziprasidone on days 5 and 13 during placebo and ketoconazole
administration.</span></div>
</div>
</div>
<p id="__p35"><span class="small-caps">anova</span> showed that the
effects of drug administration (i.e. ziprasidone plus placebo
<em>vs</em> ziprasidone plus ketoconazole) on ziprasidone AUC(0,∞)
and <em>C</em><sub>max</sub> were statistically significant
(<em>P</em>&lt; 0.02) (<a href=
"/pmc/articles/PMC2015056/table/tbl2/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl2" rid-ob=
"ob-tbl2" co-legend-rid=""><span>Table 2</span></a>). In contrast,
<span class="small-caps">anova</span> showed no significant effect
of either period or treatment on <em>t</em><sub>max</sub>, but a
slight influence of sequence on <em>t</em><sub>max</sub> was shown
to be statistically significant (<em>P</em> = 0.05; <a href=
"/pmc/articles/PMC2015056/table/tbl1/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="tbl1" rid-ob=
"ob-tbl1" co-legend-rid=""><span>Table 1</span></a>). There was no
apparent difference in ziprasidone pharmacokinetics between men and
women (data not shown).</p>
<p id="__p36" class="p p-last">Mean trough plasma ketoconazole
concentrations determined 1 day before and just before ziprasidone
administration were similar in the ketoconazole–placebo sequence
(group 1; 236–286 ng ml<sup>−1</sup>) and the placebo–ketoconazole
sequence (group 2; 278–302 ng ml<sup>−1</sup>). One day after
ziprasidone administration, mean trough ketoconazole concentrations
were approximately 2-fold higher compared with those before
ziprasidone dosing.</p>
</div>
<div id="__sec15" class="sec sec-last">
<h3>Tolerability</h3>
<p id="__p37" class="p p-first">The majority of adverse events
experienced by patients in groups 1 and 2 were of mild severity.
Two adverse events of moderate intensity were recorded; one in a
subject given ketoconazole alone (headache) and one in a subject
given ketoconazole and ziprasidone (dizziness).</p>
<p id="__p38">Mild to moderate adverse events were recorded in 2/14
(14%) subjects given placebo alone, 4/14 (29%) subjects given
ketoconazole alone, 4/13 (30%) subjects given ziprasidone with
placebo, and 10/14 (71%) subjects given ziprasidone and
ketoconazole together. The most frequent treatment-emergent adverse
events seen in subjects given ziprasidone with ketoconazole were
mild or moderate dizziness (5/14 subjects), asthenia (4/14
subjects) and somnolence (3/14 subjects). While taking ziprasidone
with placebo, subjects experienced asthenia (2/13 subjects),
dizziness (1/13 subject), and somnolence (1/13 subject). There were
no serious adverse events, treatment-emergent laboratory
abnormalities or significant changes in vital signs throughout the
study, or within a 6 day period after study completion.</p>
<p id="__p39" class="p p-last">One subject receiving ziprasidone
with placebo (group 1) experienced a single, brief episode of mild
syncope and dizziness on day 13 that was judged by the investigator
to be related to study medication. One subject receiving
ziprasidone with ketoconazole (group 2) experienced a single, brief
episode of mild syncope 8 h after ziprasidone administration on day
13. This episode resolved spontaneously within 1 min, and was
judged to be unrelated to study medication.</p>
</div>
</div>
<div id="__sec16" class="tsec sec">
<h2 class="head no_bottom_margin" id="__sec16title">Discussion</h2>
<p id="__p40" class="p p-first">Ketoconazole is a potent inhibitor
of the P450 isozyme CYP3A4. Numerous reports have demonstrated that
the concurrent administration of ketoconazole reduces the
metabolism of other drugs metabolized by this isozyme [<a href=
"#b7" rid="b7" class=" bibr popnode">7</a>, <a href="#b12" rid=
"b12" class=" bibr popnode">12</a>–<a href="#b14" rid="b14" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012733">14</a>]. The primary route of the oxidative
metabolism of ziprasidone is mediated by CYP3A4 and it is important
to investigate whether co-administration with ketoconazole would
produce clinically relevant changes in ziprasidone exposure and
safety. Dhis study examined the pharmacokinetics and safety of
ziprasidone coadministered with ketoconazole (under steady-state
conditions) or placebo in healthy volunteers.</p>
<p id="__p41">Concurrent administration of a single dose of
ziprasidone (40 mg) with multiple doses of ketoconazole (400 mg
day<sup>−1</sup>), given to attain steady-state conditions,
resulted in a modest but statistically significant increase in
ziprasidone exposure compared with concurrent administration of
ziprasidone and placebo. This change, observed as a 34% increase in
<em>C</em><sub>max</sub> and a 33% increase in AUC(0,∞)
(<em>P</em>&lt; 0.02), is considered clinically insignifi-cant.</p>
<p id="__p42">There were no statistically significant changes in
<em>t</em><sub>max</sub>, <em>t</em><sub>½,z</sub>, and
λ<sub>z</sub> when ziprasidone was given with ketoconazole. The
difference in <em>t</em><sub>max</sub> between the placebo phases
of group 1 and group 2 (7.0 h <em>vs</em> 10.0 h) represented a
statistically significant sequence effect on
<em>t</em><sub>max</sub> (<em>P</em> =0.05). However, there were no
significant treatment or period effects on <em>t</em><sub>max</sub>
and no significant sequence, treatment, or period effects on the
other pharmacokinetic parameters.</p>
<p id="__p43">In a single-dose study involving healthy volunteers,
a small (6%) increase in ziprasidone exposure was observed
following co-administration with cimetidine 800 mg (a nonspecific
CYP inhibitor), as measured by AUC(0,∞) [<a href="#b4" rid="b4"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012738">4</a>]. No statistically significant changes in
<em>C</em><sub>max</sub>, <em>t</em><sub>max</sub>, or
λ<sub>z</sub> were observed. A study on the effect of CYP3A4
induction on ziprasidone, using carbamazepine, showed a
statistically significant but modest reduction in steady-state
ziprasidone exposure; AUC(0,12 h) and <em>C</em><sub>max</sub>
decreased by 36% and 27%, respectively [<a href="#b6" rid="b6"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012731">6</a>]. However, these results suggest that
neither CYP3A4 inhibitors nor CYP3A4 inducers have a clinically
significant effect on the pharmacokinetics of ziprasidone. The
clinically insignificant effect of ketoconazole on ziprasidone
pharmacokinetics contrasts with the interaction between
ketoconazole and model CYP3A4 substrates, such as
triazolobenzodiazepines. For example, administration of
ketoconazole 400 mg day<sup>−1</sup> for 4 days increases the AUC
of a single dose of triazolam by &gt; 2000%[<a href="#b15" rid=
"b15" class=" bibr popnode">15</a>].</p>
<p id="__p44">Trough plasma ketoconazole concentrations were
elevated during concurrent administration with ziprasidone. This
increase is believed to be related to the consumption of the
standardized high-fat breakfast prior to ketoconazole dosing on the
days when ziprasidone was administered, leading to enhanced drug
solubilization, absorption, and bioavailability [<a href="#b16"
rid="b16" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012742">16</a>, <a href="#b17" rid="b17" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012740">17</a>].</p>
<p id="__p45">The modest increase in ziprasidone exposure following
ketoconazole administration is consistent with inhibition of CYP3A4
by ketoconazole and the results of <em>in vitro</em> studies, which
show that CYP3A4 is the major CYP isoform involved in ziprasidone
metabolism. Other CYP isoforms (CYP1A2, CYP2C9, CYP2C19, and
CYP2D6) are unlikely to be implicated in ziprasidone metabolism
based on the evidence of human liver microsome studies [<a href=
"#b3" rid="b3" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012743">3</a>]. Isoform-selective substrate studies
conducted in human hepatic microsomes determined that ziprasidone
concentrations required to inhibit CYP3A4 and CYP2D6 would be at
least 1500-fold higher than those achievable clinically [<a href=
"#b3" rid="b3" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012736">3</a>]. The <em>K</em><sub>i</sub> for
ziprasidone at CYP3A4 is 64 µ<span class=
"small-caps">m</span>[<a href="#b3" rid="b3" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311012744">3</a>]. Thus, ziprasidone is not expected to
inhibit the oxidative metabolism of CYP3A4 substrates.</p>
<p id="__p46">The majority of adverse events reported were of mild
intensity. Adverse events most often reported in subjects receiving
ziprasidone and ketoconazole were dizziness, asthenia, and
somnolence. There were no treatment-related laboratory
abnormalities or abnormal vital signs during the study and 6 days
after study completion.</p>
<p id="__p47" class="p p-last">In conclusion, ziprasidone is
oxidatively metabolized by CYP3A4, and the potent CYP3A4 inhibitor,
ketoconazole, does not cause clinically significant increases in
ziprasidone exposure following single oral doses of 40 mg. This
suggests that ziprasidone dose modifications are unlikely to be
necessary in patients receiving ketoconazole or other potent CYP3A4
inhibitors.</p>
</div>
<div id="__ref-listid1500705" class="tsec sec">
<h2 class="head no_bottom_margin" id="__ref-listid1500705title">
References</h2>
<div class="ref-list-sec sec" id="reference-list">
<div class="ref-cit-blk half_rhythm" id="b1">1. <span class=
"element-citation">Prakash C, Kamel A, Anderson W, Fouda H.
Characterization of metabolites of CP-88 059 in rat using
HPLC/RAM/ESI/MS/MS. Proceedings of the 42nd ASMS Conference on Mass
Spectrometry and Allied Topics. Chicago, USA.</span></div>
<div class="ref-cit-blk half_rhythm" id="b2">2. <span class=
"element-citation">Prakash C, Kamel A, Cui D, Whalen RD, Miceli JJ,
Tweedie DJ. Ziprasidone metabolism and cytochrome P450 isoforms.
<span><span class="ref-journal">Biol Psychiatry.</span>
1997;<span class="ref-vol">42</span>:40S.</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b3">3. <span class=
"element-citation">Prakash C, Kamel A, Cui D, Whalen RD, Miceli JJ,
Tweedie D. Identification of the major human liver cytochrome P450
isoform (s) responsible for the formation of the primary
metabolites of ziprasidone and prediction of possible drug
interactions. <span><span class="ref-journal">Br J Clin
Pharmacol.</span> 2000;<span class="ref-vol">49</span>(Suppl.
1):35S–42S.</span> <span class="nowrap ref pmc">[<a class=
"int-reflink" href="/pmc/articles/PMC2015052/">PMC free
article</a>]</span> <span class="nowrap ref pubmed">[<a href=
"/pubmed/10771452" target="pmc_ext" ref=
"reftype=pubmed&amp;article-id=2015056&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b4">4. <span class=
"element-citation">Wilner KD, Hansen RA, Folger CJ, Geoffroy P. The
pharmacokinetics of ziprasidone in healthy volunteers treated with
cimetidine or antacid. <span><span class="ref-journal">Br J Clin
Pharmacol.</span> 2000;<span class="ref-vol">49</span>(Suppl.
1):57S–60S.</span> <span class="nowrap ref pmc">[<a class=
"int-reflink" href="/pmc/articles/PMC2015049/">PMC free
article</a>]</span> <span class="nowrap ref pubmed">[<a href=
"/pubmed/10771455" target="pmc_ext" ref=
"reftype=pubmed&amp;article-id=2015056&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b5">5. <span class=
"element-citation">Muirhead GJ, Harness J, Holt PR, Oliver S,
Anziano RJ. Ziprasidone and the pharmacokinetics of a combined oral
contraceptive. <span><span class="ref-journal">Br J Clin
Pharmacol.</span> 2000;<span class="ref-vol">49</span>(Suppl.
1):49S–56S.</span> <span class="nowrap ref pmc">[<a class=
"int-reflink" href="/pmc/articles/PMC2015051/">PMC free
article</a>]</span> <span class="nowrap ref pubmed">[<a href=
"/pubmed/10771454" target="pmc_ext" ref=
"reftype=pubmed&amp;article-id=2015056&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b6">6. <span class=
"element-citation">Miceli JJ, Laurent A. The effect of
carbamazepine on the steady-state pharmacokinetics of ziprasidone
in healthy volunteers. <span><span class="ref-journal">Br J Clin
Pharmacol.</span> 2000;<span class="ref-vol">49</span>(Suppl.
1):65S–70S.</span> <span class="nowrap ref pmc">[<a class=
"int-reflink" href="/pmc/articles/PMC2015057/">PMC free
article</a>]</span> <span class="nowrap ref pubmed">[<a href=
"/pubmed/10771457" target="pmc_ext" ref=
"reftype=pubmed&amp;article-id=2015056&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b7">7. <span class=
"element-citation">Bennett JE. Antimicrobial agents: antifungal
agents. In: Hardman JJG, Limbird LE, Molinoff PB, Ruddon RW,
Goodman Gilman A, editors. <span class="ref-journal">The
Pharmacological Basis of Therapeutics.</span> 9. UAS: McGraw-Hill;
1996. pp. 1175–1190.</span></div>
<div class="ref-cit-blk half_rhythm" id="b8">8. <span class=
"element-citation">Ament PW, Paterson A. Drug interactions with the
non-sedating antihistamines. <span><span class="ref-journal">Am Fam
Physician.</span> 1997;<span class=
"ref-vol">56</span>:223–231.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9225677" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015056&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b9">9. <span class=
"element-citation">Sadowski DC. Drug interactions with antacids.
Mechanisms and clinical significance. <span><span class=
"ref-journal">Drug Safety.</span> 1994;<span class=
"ref-vol">11</span>:395–407.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/7727050" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015056&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b10">10. <span class=
"element-citation">Metropolitan height and weight tables
<span><span class="ref-journal">Stat Bull Metrop Life Found.</span>
1983;<span class="ref-vol">64</span>:3–9.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/6623350" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015056&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b11">11. <span class=
"element-citation">Janiszewski JS, Fouda HG, Cole RO. Development
and validation of a high-sensitivity assay for an antipsychotic
agent, CP-88,059, with solid-phase excavation and narrow-bore
high-performance liquid chromatography. <span><span class=
"ref-journal">J Chromatogr.</span> 1995;<span class=
"ref-vol">668</span>:133–139.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/7550970" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015056&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b12">12. <span class=
"element-citation">Babe KS, Serafin WE. Histamine, Bradykinin, and
their atagonists. In: Hardman JJG, Limbird LE, Molinoff PB, Ruddon
RW, Goodman Gilman A, editors. <span class="ref-journal">The
Pharmacological Basis of Therapeutics.</span> 9. USA: McGraw-Hill;
1996. pp. 581–600.</span></div>
<div class="ref-cit-blk half_rhythm" id="b13">13. <span class=
"element-citation">Ereshefsky L. Pharmacokinetics and drug
interactions: update for new antipsychotics. <span><span class=
"ref-journal">J Clin Psychiatry.</span> 1996;<span class=
"ref-vol">57</span>:12–25.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/8941167" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015056&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b14">14. <span class=
"element-citation">Raeissi SD, Guo Z, Dobson GL, Artursson P,
Hidalgo IJ. Comparison of CYP3A activities in a subclone of Caco-2
cells (TC7) and human Intestine. <span><span class=
"ref-journal">Pharm Res.</span> 1997;<span class=
"ref-vol">14</span>:1019–1025.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9279883" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015056&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b15">15. <span class=
"element-citation">Preskorn SH. <span class="ref-journal">Clinical
Pharmacology of Selective Serotonin Reuptake Inhibitors.</span>
Caddo, OK, USA: Professional Communications; 1996.</span></div>
<div class="ref-cit-blk half_rhythm" id="b16">16. <span class=
"element-citation">Daneshmend TK, Warnock DW, Ene MD, et al.
Influence of food on the pharmacokinetics of ketoconazole.
<span><span class="ref-journal">Antimicrob Agents Chemother.</span>
1984;<span class="ref-vol">25</span>:1–3.</span> <span class=
"nowrap ref pmc">[<a class="int-reflink" href=
"/pmc/articles/PMC185421/">PMC free article</a>]</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/6322675" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=2015056&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="b17">17. <span class=
"element-citation">Lelawongs P, Barone AB, Colaizzi JL, et al.
Effects of food and gastric acidity on absorption of orally
administered ketoconazole. <span><span class="ref-journal">Clin
Pharmacol.</span> 1988;<span class=
"ref-vol">7</span>:228–235.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/3356120" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=2015056&amp;issue-id=151586&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
</div>
</div>
</div>
<!--post-content-->
<hr class="whole_rhythm no_bottom_margin" />
<div class="courtesy-note no_margin small">Articles from
<span class="acknowledgment-journal-title">British Journal of
Clinical Pharmacology</span> are provided here courtesy of
<strong>British Pharmacological Society</strong></div>
</div>
</div>
<!-- Book content --></div>
<div id="rightcolumn" class="four_col col last">
<!-- Custom content above discovery portlets -->
<div class="col6"></div>
<div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi=
"http://www.w3.org/2001/XMLSchema-instance">
<div class="try-button"><a href=
"/pmc/articles/PMC2015056/?report=reader"><img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/3838809"
alt="PubReader format: click here to try" /></a></div>
<div class="format-menu">
<h2>Formats:</h2>
<ul>
<li class="selected">Article</li>
<li style="list-style: none">|</li>
<li><a href=
"/pmc/articles/PMC2015056/?report=reader">PubReader</a></li>
<li style="list-style: none">|</li>
<li class="epub-link"><a href="/pmc/articles/PMC2015056/epub/">ePub
(beta)</a></li>
<li style="list-style: none">|</li>
<li><a href="/pmc/articles/PMC2015056/pdf/bcp0049-071S.pdf">PDF
(115K)</a></li>
<li style="list-style: none">|</li>
<li><a href="#" data-citationid="PMC2015056" class=
"citationexporter ctxp">Citation</a></li>
</ul>
</div>
</div>
<div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi=
"http://www.w3.org/2001/XMLSchema-instance" class="share-buttons">
<h2>Share</h2>
<ul>
<li class="facebook"><a href=
"https://www.facebook.com/sharer/sharer.php?u=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2015056%2F">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047626"
alt="Share on Facebook" /> Facebook</a></li>
<li class="twitter"><a href=
"https://twitter.com/intent/tweet?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2015056%2F&amp;text=The%20effects%20of%20ketoconazole%20on%20ziprasidone%20pharmacokinetics%20%E2%80%94a%20placebo-controlled%20crossover%20study%20in%20healthy%20volunteers">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047627"
alt="Share on Twitter" /> Twitter</a></li>
<li class="gplus"><a href=
"https://plus.google.com/share?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2015056%2F">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047628"
alt="Share on Google Plus" /> Google+</a></li>
</ul>
</div>
<div id="ajax-portlets" data-pmid="10771458" data-aiid="2015056"
data-aid="2015056" data-iid="151586" data-domainid="279"
data-domain="brjclinpharm" data-accid="PMC2015056" data-md5=
"cfcc4ec2fc559cdea999c1d337433980"></div>
<!-- Custom content below discovery portlets -->
<div class="col7"></div>
</div>
</div>
<!-- Custom content after all -->
<div class="col8"></div>
<div class="col9"></div>
<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js">
</script> <script>
<![CDATA[
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
]]>
</script>
<div id="body-link-poppers"></div>
</div>
<div class="bottom">
<div id="NCBIFooter_dynamic">
<div class="breadcrumbs">You are here: <span id=
"breadcrumb_text"><a href="/guide/">NCBI</a> &gt; <a href=
"http://www.ncbi.nlm.nih.gov/guide/literature/">Literature</a> &gt;
<a href="http://www.ncbi.nlm.nih.gov/pmc/">PubMed Central
(PMC)</a></span></div>
<a id="help-desk-link" class="help_desk jig-ncbihelpwindow" target=
"_blank" href=
"/sites/ehelp?&amp;Ncbi_App=pmc&amp;Db=pmc&amp;Page=literature&amp;Snapshot=/projects/PMC/PMCViewer@4.35&amp;Time=2016-04-01T09:54:11-04:00&amp;Host=ptpmc202">Write
to the Help Desk</a></div>
<div class="footer" id="footer">
<div class="subfooter"></div>
<script type="text/javascript" src=
"/portal/portal3rc.fcgi/static/js/preloaderWidget.js">
</script>
<div id="external-disclaimer" class="offscreen_noflow">External
link. Please review our <a href=
"http://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div>
<div id="ncbifooter" class="contact_info">
<div id="footer-contents-right">
<div id="nlm_thumb_logo"><a href="http://www.nlm.nih.gov" title=
"NLM">NLM</a></div>
<div id="nih_thumb_logo"><a href="http://www.nih.gov" title=
"NIH">NIH</a></div>
<div id="hhs_thumb_logo"><a href="http://www.dhhs.gov" title=
"DHHS">DHHS</a></div>
<div id="usagov_thumb_logo"><a href="http://www.usa.gov" title=
"USA.gov">USA.gov</a></div>
</div>
<div id="footer-contents-left"><a href=
"/About/disclaimer.html">Copyright</a> | <a href=
"/About/disclaimer.html#disclaimer">Disclaimer</a> | <a href=
"http://www.nlm.nih.gov/privacy.html" class="newdomain">Privacy</a>
| <a href="/guide/browsers/">Browsers</a> | <a href=
"http://www.nlm.nih.gov/accessibility.html">Accessibility</a> |
<a href="/About/glance/contact_info.html">Contact</a>
<p class="address vcard"><span class="url"><a class=
"fn url newdomain" href="http://www.ncbi.nlm.nih.gov">National
Center for Biotechnology Information</a>,</span> <span class=
"org url"><a href="http://www.nlm.nih.gov/">U.S. National Library
of Medicine</a></span> <span class="adr"><span class=
"street-address">8600 Rockville Pike</span>, <span class=
"locality">Bethesda</span> <span class="region">MD</span>,
<span class="postal-code">20894</span> <span class=
"country-name">USA</span></span></p>
</div>
</div>
<script type="text/javascript" src=
"/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1">
</script> <script type="text/javascript" src=
"/portal/portal3rc.fcgi/static/js/hfjs2.js">
</script></div>
</div>
</div>
<!--/.page--></div>
<!--/.wrap--></div>
<!-- /.twelve_col --></div>
<!-- /.grid -->
 <!-- BESelector tab -->
 <noscript><img alt="statistics" src=
"/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=brjclinpharm&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC2015056/&amp;ncbi_app=pmc" />
</noscript> <!-- usually for JS scripts at page bottom -->
 <!--<component id="PageFixtures" label="styles"></component>-->
 
<!-- F4FC5E3F6FE7D821_0012SID /projects/PMC/PMCViewer@4.35 ptpmc202 v4.1.r480124 Mon, Sep 28 2015 02:46:19 -->
 <script type="text/javascript" src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/js/3879255/3728312/3818874/3821238/4064716/4072593/4064449/3921943/4070217/4065628.js"
snapshot="pmc">
</script>
</body>
</html>
